The Stamford Hospital
- Type
- Teaching hospital
- Where
- Stamford, CT
- Medicare CCN
- 070006
- Received
- $608,360 in 85 records, 2021 ($8,897 general, $599,462 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STAMFORD HOSPITAL Fuzzy (name and state)
- Plan sponsor: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Nonprofit: STAMFORD HOSPITAL Fuzzy (name and state)
- Trademark owner: The Stamford Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 23 | $8,897 |
| 2021 | Research payment | 62 | $599,462 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genentech, Inc. | 6 | $376,361 | 2021 |
| F. Hoffmann-La Roche AG | 7 | $95,871 | 2021 |
| Incyte Corporation | 4 | $24,859 | 2021 |
| AKEBIA THERAPEUTICS INC | 18 | $24,095 | 2021 |
| AstraZeneca Pharmaceuticals LP | 3 | $18,894 | 2021 |
| Celgene Corporation | 2 | $17,803 | 2021 |
| EMD Serono, Inc. | 7 | $16,064 | 2021 |
| Janssen Research & Development, LLC | 2 | $8,932 | 2021 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $7,630 | 2021 |
| CSL Behring | 6 | $6,963 | 2021 |
| Tandem Diabetes Care, Inc. | 13 | $6,250 | 2021 |
| ABBVIE INC. | 3 | $1,225 | 2021 |
| Boston Scientific Corporation | 3 | $987 | 2021 |
| Johnson & Johnson Health Care Systems Inc. | 2 | $537 | 2021 |
| Ethicon US, LLC | 1 | $500 | 2021 |
| Medtronic, Inc. | 2 | $500 | 2021 |
| Olympus America Inc. | 1 | $321 | 2021 |
| Amgen Inc. | 1 | $275 | 2021 |
| Siemens Medical Solutions USA, Inc. | 1 | $226 | 2021 |
| Helena Laboratories Corporation | 1 | $36 | 2021 |
| Bio-Rad Laboratories, Inc. | 1 | $25 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 62 | $599,462 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 15 | $6,750 |
| Space rental or facility fees (teaching hospital only) | 2 | $1,000 |
| Debt forgiveness | 4 | $789 |
| Gift | 1 | $321 |
| Food and Beverage | 1 | $36 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $3,635 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate th | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $226 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-29 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $432 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-22 | Johnson & Johnson Health Care Systems Inc. | $105 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-15 | EMD Serono, Inc. | $550 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 | |
| 2021-12-15 | EMD Serono, Inc. | $225 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 | |
| 2021-12-13 | Medtronic, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 770G System Device, Durable Pump | 2021 | |
| 2021-12-09 | AKEBIA THERAPEUTICS INC | $7,200 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-12-09 | AKEBIA THERAPEUTICS INC | $810 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-12-08 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-11-30 | Bayer Healthcare Pharmaceuticals Inc. | $7,630 | Research payment | Cash or cash equivalent | Non-Covered | BAY1002670 Long term Safety vs SoC | 2021 |
| 2021-11-19 | Genentech, Inc. | $20,035 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-11-18 | Genentech, Inc. | $6,461 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2021 |
| 2021-11-11 | Genentech, Inc. | $2,850 | Research payment | Cash or cash equivalent | Drug | SINGLE AGENT GDC 9545 VS ENDOCRINE MONOTHERAPY ADJUVANT TREATMENT IN HR EBC | 2021 |
| 2021-11-10 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-11-05 | Ethicon US, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VISTASEAL Biological, Biosurgical | 2021 | |
| 2021-11-03 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-10-29 | Bio-Rad Laboratories, Inc. | $25 | Debt forgiveness | Cash or cash equivalent | Biotestcell 1 & 2 Device, Antiglobulin test | 2021 | |
| 2021-10-27 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-10-26 | CSL Behring | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-10-12 | AKEBIA THERAPEUTICS INC | $225 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-10-12 | AKEBIA THERAPEUTICS INC | $216 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-10-11 | Genentech, Inc. | $220 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-10-05 | F. Hoffmann-La Roche AG | $54,791 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-10-05 | F. Hoffmann-La Roche AG | $13,673 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-10-05 | F. Hoffmann-La Roche AG | $6,758 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-10-05 | Janssen Research & Development, LLC | $4,527 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-10-05 | F. Hoffmann-La Roche AG | $3,500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-10-05 | F. Hoffmann-La Roche AG | $770 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-10-01 | AstraZeneca Pharmaceuticals LP | $10,261 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate th | 2021 |
| 2021-09-29 | Incyte Corporation | $9,311 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2021 | |
| 2021-09-29 | Incyte Corporation | $9,311 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2021 | |
| 2021-09-22 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-09-21 | Medtronic, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 770G System Device, Durable Pump | 2021 | |
| 2021-09-20 | EMD Serono, Inc. | $3,053 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | PATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-2020 | 2021 |
| 2021-09-14 | Helena Laboratories Corporation | $36 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-09-10 | Janssen Research & Development, LLC | $4,405 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-09-09 | F. Hoffmann-La Roche AG | $5,060 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-09-08 | Tandem Diabetes Care, Inc. | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-09-07 | Boston Scientific Corporation | $270 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | INVESTIGATIONAL STUDY TO INFORM GUIDANCE IN PROGRAMMING HEAR | 2021 |
| 2021-09-02 | AKEBIA THERAPEUTICS INC | $675 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-09-02 | AKEBIA THERAPEUTICS INC | $648 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-08-18 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-08-05 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | A Multicenter, Observational Cohort Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Att | 2021 |
| 2021-08-05 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | A Multicenter, Observational Cohort Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Att | 2021 |
| 2021-08-05 | ABBVIE INC. | $225 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | A Multicenter, Observational Cohort Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Att | 2021 |
| 2021-07-22 | AKEBIA THERAPEUTICS INC | $542 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-07-15 | AKEBIA THERAPEUTICS INC | $2,168 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-07-15 | AKEBIA THERAPEUTICS INC | $1,620 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-07-15 | AKEBIA THERAPEUTICS INC | $575 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-07-13 | AKEBIA THERAPEUTICS INC | $675 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-07-13 | AKEBIA THERAPEUTICS INC | $648 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-07-09 | Genentech, Inc. | $338,250 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-07-08 | AKEBIA THERAPEUTICS INC | $882 | Research payment | Cash or cash equivalent | AKB-6548-CI-0014 | 2021 | |
| 2021-06-24 | AKEBIA THERAPEUTICS INC | $1,005 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-06-24 | AKEBIA THERAPEUTICS INC | $750 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-06-22 | AKEBIA THERAPEUTICS INC | $450 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-06-22 | AKEBIA THERAPEUTICS INC | $432 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-06-16 | CSL Behring | $2,530 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-06-16 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-06-16 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-06-16 | CSL Behring | $225 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-06-04 | EMD Serono, Inc. | $6,461 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 | |
| 2021-06-04 | EMD Serono, Inc. | $2,850 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 | |
| 2021-06-04 | EMD Serono, Inc. | $2,725 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 | |
| 2021-06-04 | EMD Serono, Inc. | $200 | Research payment | Cash or cash equivalent | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 | |
| 2021-05-17 | Boston Scientific Corporation | $224 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | INVESTIGATIONAL STUDY TO INFORM GUIDANCE IN PROGRAMMING HEAR | 2021 |
| 2021-04-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-04-06 | F. Hoffmann-La Roche AG | $11,317 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ALL COMERS SSF | 2021 |
| 2021-03-18 | AstraZeneca Pharmaceuticals LP | $4,998 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2021 |
| 2021-03-17 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-03-15 | Boston Scientific Corporation | $493 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | INVESTIGATIONAL STUDY TO INFORM GUIDANCE IN PROGRAMMING HEAR | 2021 |
| 2021-03-11 | Celgene Corporation | $5,803 | Research payment | Cash or cash equivalent | Pomalyst Drug, Hematology | A phase 2, multicenter, multi-cohort, open-label s | 2021 |
| 2021-03-09 | AKEBIA THERAPEUTICS INC | $4,574 | Research payment | Cash or cash equivalent | AKB-6548-CI-0015 | 2021 | |
| 2021-02-23 | CSL Behring | $708 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2021 | |
| 2021-02-10 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-02-03 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-02-02 | Celgene Corporation | $12,000 | Research payment | Cash or cash equivalent | Connect MM- The Multiple Myeloma Disease Registry | 2021 | |
| 2021-01-22 | Genentech, Inc. | $8,545 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2021 |
| 2021-01-22 | Amgen Inc. | $275 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2021 |
| 2021-01-20 | Incyte Corporation | $5,072 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2021 | |
| 2021-01-20 | Incyte Corporation | $1,165 | Research payment | Cash or cash equivalent | PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED | 2021 | |
| 2021-01-06 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2021 | |
| 2021-01-01 | Olympus America Inc. | $321 | Gift | In-kind items and services | Olympus Device, Energy | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) Stamford, CT | County Western Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 137,144 | 627,071 | 3,624,508 |
| Population, 2020 census P1 | 135,470 | - | 3,605,944 |
| Median age B01002 | 38.4 | 41.5 | 41.1 |
| Under 18 B01001 | 18.4% | 21.8% | 20.2% |
| 65 and over B01001 | 16.2% | 17.4% | 18.5% |
| Households B11001 | 55,291 | 235,379 | 1,434,007 |
| Foreign born B05002 | 31.3% | 23.8% | 15.7% |
| Median household income B19013 | $111,586 | $128,188 | $95,781 |
| Median family income B19113 | $126,493 | $161,625 | $122,706 |
| Per capita income B19301 | $67,068 | $82,266 | $55,915 |
| Poverty rate B17001 | 10.1% | 7.5% | 10.0% |
| Unemployment rate B23025 | 4.9% | 5.3% | 5.6% |
| Civilian labor force B23025 | 81,944 | 346,557 | 1,959,490 |
| Mean commute (minutes) B08013 | 28.5 | 30.8 | 26.5 |
| Bachelor's degree or higher B15003 | 51.7% | 55.5% | 42.5% |
| Housing units B25001 | 58,655 | 251,530 | 1,541,822 |
| Owner-occupied B25003 | 48.8% | 66.4% | 66.5% |
| Renters B25003 | 51.2% | 33.6% | 33.5% |
| Median home value B25077 | $624,400 | $652,900 | $366,900 |
| Median gross rent B25064 | $2,276 | $2,110 | $1,488 |
| White, not Hispanic B03002 | 43.2% | 58.6% | 61.9% |
| Black B03002 | 17.7% | 9.3% | 9.8% |
| Hispanic or Latino B03002 | 28.3% | 20.5% | 18.3% |
| Asian B03002 | 7.3% | 5.4% | 4.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.
Comments